II

Ishara Investments LP

High-turnover traderSector-focusedMomentum follower

Total reported value

$105.6M

Reporting period: 2026-03-31 · Number of holdings: 37

Ishara Investments LP disclosed 37 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $105.6M and a quarterly turnover rate of 98.2%.

Personality snowflake

Concentration
18.68
Portfolio Stability
98.23
Momentum/Contrarian
100
Sector conviction
100
Diversification
72
Sizing Uniformity
91.63

Recent moves

  • Trim ANNX

    -76.8%　-$2.8M

  • Trim PTCT

    -71.5%　-$2.0M

  • Trim BMRN

    -18.0%　-$1.3M

  • Trim ACAD

    -23.1%　-$1.5M

  • Add RARE

    +248.5%　$2.5M

  • Add VSTM

    +203.7%　$2.3M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

Showing top 36 holdings (of 37 total)

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1PRAXPraxis Precision Medicines IStock-Other13.13%-0.35%+7.63%
2AXSMAxsome Therapeutics INCStock-Healthcare6.56%+6.56%NEW
3XERSXeris Biopharma Holdings INCStock-Other5.63%-1.55%+28.13%
44XC1Kalvista Pharmaceuticals INCStock-Other5.27%+5.27%NEW
5AM6Amicus Therapeutics INCStock-Other5.05%-0.81%+2.50%
6BMRNBiomarin Pharmaceutical INCStock-Healthcare4.39%-2.41%-18.00%
7VSTMVerastem INCStock-Other4.11%+1.73%+203.70%
8RAREUltragenyx Pharmaceutical InStock-Other3.46%+2.14%+248.50%
9ARWRArrowhead Pharmaceuticals InStock-Healthcare3.29%+3.29%NEW
10PCVXVaxcyte INCStock-Other3.16%+0.52%+14.80%
11VERAVera Therapeutics INCStock-Other3.12%+3.12%NEW
12TVTXTravere Therapeutics INCStock-Other3.11%+3.11%NEW
13MLTXMoonlake ImmunotherapeuticsStock-Other3.08%+3.08%NEW
14ZNTLZentalis Pharmaceuticals INCStock-Other2.72%+0.68%-6.82%
15SRRKScholar Rock Holding CORPStock-Other2.67%+2.67%NEW
16ACADAcadia Pharmaceuticals INCStock-Healthcare2.59%-2.30%-23.13%
17ARDXArdelyx INCStock-Other2.56%+2.56%NEW
18MLYSMineralys Therapeutics INCStock-Other2.10%+2.10%NEW
19GMABGenmab A/s -sp AdrStock-Other2.08%—+17.14%
20DBVTDbv Technologies Sa-spon AdrStock-Other2.03%+2.03%NEW
21CPRXCatalyst Pharmaceuticals INCStock-Healthcare1.92%+1.92%NEW
22SIONSionna Therapeutics INCStock-Other1.87%+1.87%NEW
23CTNMContineum Therapeutics Inc-aStock-Other1.76%+1.76%NEW
24ALNYAlnylam Pharmaceuticals INCStock-Healthcare1.61%+1.61%NEW
25LGNDLigand PharmaceuticalsStock-Healthcare1.55%+1.55%NEW
26EWTXEdgewise Therapeutics INCStock-Other1.47%—-15.17%
27✓ Immatics NVStock-Other1.43%+0.47%+92.19%
28LXRXLexicon Pharmaceuticals INCStock-Other1.33%+0.17%+2.50%
29BEAMBeam Therapeutics INCStock-Other1.29%—+14.80%
30ORICOric Pharmaceuticals INCStock-Other1.23%—-35.94%
31NAMSNewAmsterdam Pharma Company N.V.Stock-Other1.12%—+23.00%
32ANNXAnnexon INCStock-Other0.91%-3.40%-76.77%
33IDYAIdeaya Biosciences INCStock-Other0.78%+0.78%NEW
34SLNSilence Therapeutics Plc-adrStock-Other0.70%-0.97%-41.46%
35PTCTPtc Therapeutics INCStock-Healthcare0.66%-2.47%-71.53%
36GOSSGossamer Bio INCStock-Other0.26%+0.26%NEW

Holding changes this quarter

Ishara Investments LP's most significant position changes for 2026-03-31: New buy: Axsome Therapeutics INC (AXSM); New buy: Kalvista Pharmaceuticals INC (4XC1); Sold out: Nuvation Bio INC (NUVB); New buy: Arrowhead Pharmaceuticals In (ARWR); New buy: Vera Therapeutics INC (VERA).

Position changes disclosed by Ishara Investments LP for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1RAREUltragenyx Pharmaceutical In+2.1%+248.50%Add
2VSTMVerastem INC+1.7%+203.70%Add
3ZNTLZentalis Pharmaceuticals INC+0.7%-6.82%Trim
4PCVXVaxcyte INC+0.5%+14.80%Add
5✓ Immatics NV+0.5%+92.19%Add
6LXRXLexicon Pharmaceuticals INC+0.2%+2.50%Add
7PRAXPraxis Precision Medicines I-0.4%+7.63%Add
8AM6Amicus Therapeutics INC-0.8%+2.50%Add
9SLNSilence Therapeutics Plc-adr-1%-41.46%Trim
10XERSXeris Biopharma Holdings INC-1.6%+28.13%Add
11ACADAcadia Pharmaceuticals INC-2.3%-23.13%Trim
12BMRNBiomarin Pharmaceutical INC-2.4%-18.00%Trim
13PTCTPtc Therapeutics INC-2.5%-71.53%Trim
14ANNXAnnexon INC-3.4%-76.77%Trim
15AXSMAxsome Therapeutics INC—NEWNew buy
164XC1Kalvista Pharmaceuticals INC—NEWNew buy
17NUVBNuvation Bio INC—EXITSold out
18ARWRArrowhead Pharmaceuticals In—NEWNew buy
19VERAVera Therapeutics INC—NEWNew buy
20TVTXTravere Therapeutics INC—NEWNew buy
21MLTXMoonlake Immunotherapeutics—NEWNew buy
22SRRKScholar Rock Holding CORP—NEWNew buy
23BBIOBridgebio Pharma INC—EXITSold out
24ARDXArdelyx INC—NEWNew buy
25UTHRUnited Therapeutics CORP—EXITSold out
26BCRXBiocryst Pharmaceuticals INC—EXITSold out
27MLYSMineralys Therapeutics INC—NEWNew buy
28DBVTDbv Technologies Sa-spon Adr—NEWNew buy
29SNDXSyndax Pharmaceuticals INC—EXITSold out
30CPRXCatalyst Pharmaceuticals INC—NEWNew buy
31SIONSionna Therapeutics INC—NEWNew buy
32TARSTarsus Pharmaceuticals INC—EXITSold out
33APOGApogee Enterprises INC—EXITSold out
34CTNMContineum Therapeutics Inc-a—NEWNew buy
35INSMInsmed INC—EXITSold out
36ALNYAlnylam Pharmaceuticals INC—NEWNew buy
37LGNDLigand Pharmaceuticals—NEWNew buy
38CORTCorcept Therapeutics INC—EXITSold out
39APLSUSDApellis Pharmaceuticals INC—EXITSold out
40DNLIDenali Therapeutics INC—EXITSold out
41ASNDAscendis Pharma A/S—EXITSold out
42BHVNBiohaven Ltd.—EXITSold out
43DNTHDianthus Therapeutics INC—EXITSold out
44NKTRNektar Therapeutics—EXITSold out
45IDYAIdeaya Biosciences INC—NEWNew buy
46AGIOAgios Pharmaceuticals INC—EXITSold out
47IMVTImmunovant INC—EXITSold out
48OLMAOlema Pharmaceuticals INC—EXITSold out
49ARQTArcutis Biotherapeutics INC—EXITSold out
50GOSSGossamer Bio INC—NEWNew buy

FAQ

What is Ishara Investments LP and what type of investor is it?
Ishara Investments LP is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $105.6M, spread across 37 disclosed positions.
What are Ishara Investments LP's largest equity positions?
Based on the latest 13F filing, Ishara Investments LP's top holdings by market value are: 1. Praxis Precision Medicines I (PRAX) — $13.9M (13.1%) 2. Axsome Therapeutics INC (AXSM) — $6.9M (6.6%) 3. Xeris Biopharma Holdings INC (XERS) — $5.9M (5.6%) 4. Kalvista Pharmaceuticals INC (4XC1) — $5.6M (5.3%) 5. Amicus Therapeutics INC (AM6) — $5.3M (5.0%)
What changes did Ishara Investments LP make in its most recent portfolio filing?
In the latest reported quarter, Ishara Investments LP made 50 notable position adjustments: 17 new positions were initiated, 8 existing holdings were added to, 6 positions were partially reduced, and 19 were completely exited. The largest of these moves: New buy: Axsome Therapeutics INC (AXSM); New buy: Kalvista Pharmaceuticals INC (4XC1); Sold out: Nuvation Bio INC (NUVB); New buy: Arrowhead Pharmaceuticals In (ARWR); New buy: Vera Therapeutics INC (VERA)
What sectors does Ishara Investments LP focus on?
Ishara Investments LP is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%